Cognivue

09/12/2025

September is World Alzheimer’s Month — a reminder that early detection is power. Alzheimer’s pathology can begin years before symptoms appear [1], making timely and informed risk identification absolutely critical.

In a recent NeurologyLive interview, Dr. James Galvin discusses the Cognivue Amyloid Risk Measure (CARM*)—a newly added feature on Cognivue Clarity’s 10-minute computerized assessment. CARM provides an estimate of the likelihood of amyloid positivity, supporting clinicians in identifying patients who may benefit from confirmatory testing or referral. This helps streamline decision-making and prioritize care pathways earlier in the journey.

📖 Read the full article: Predicting Amyloid Positivity with CARM: Clinical Insights from James Galvin
https://bit.ly/4m0hIRb

🎥 Want to explore CARM further?
Join our upcoming webinar, where we’ll unpack how this risk measure supports clinical and research pathways toward early detection and intervention.
Register here: https://bit.ly/3VjnT7C

Let’s use this World Alzheimer’s Month to power more informed, proactive care. The earlier we act, the better the outcomes.


*patent pending
References: [1] Alzheimer’s Association. 2025 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2025;21(5).

The professor of neurology at the Miami Miller School of Medicine discussed how the Cognivue Amyloid Risk Measure (CARM) may help predict amyloid presence and informs diagnosis, trial eligibility, and early treatment pathways.

09/10/2025

🧠 Coming Soon: Webinar #2 of 5
What if a quick cognitive test could help detect Alzheimer’s risk—helping avoid unnecessary or inappropriate testing and the time, money, and worry that come with it?

On September 18, join James E. Galvin, MD, MPH, Chief Scientific Officer at Cognivue, for:
📘 From Screening to Stratification: CARM's Role in Advancing Alzheimer’s Risk Identification

🎥 Join live or watch on demand: https://bit.ly/3HLMJKh

09/02/2025

🧠 September is World Alzheimer’s Month — a time to raise awareness, break stigma, and highlight the importance of early brain health conversations.

At Cognivue, we are committed to advancing early detection of cognitive impairment and empowering healthcare providers and patients to take action sooner. Part of that commitment means helping to de-stigmatize brain health—making conversations about cognition approachable and proactive rather than fearful.

As our VP of Sales, Patrick Lawler, shares in this video: “It’s scarier to not talk about it.”

Alzheimer’s begins 20 years or more before symptoms develop.[1] That’s why getting a baseline cognitive screenings early—just like checking blood pressure or cholesterol—is so important.

The good news? Research suggests that up to 45% of dementia risk is potentially modifiable.[2] By having the conversation sooner, we can take steps that may slow, delay, or even prevent decline.

👉 Watch this impactful video from Growing Bolder Day Jacksonville: https://bit.ly/47c7SrC

Together, let’s make brain health part of routine health. 💜



References: [1] Alzheimer’s Association. 2025 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2025;21(5). [2] Livingston G, Huntley J, Liu K, et al. (2024). Dementia Prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 404(10452), 572-628.

08/26/2025

🔔 Only 2 Weeks Away! 🔔
Don’t miss our upcoming Cognivue webinar:
“Decoding Tinnitus: The Unseen Connection to Brain Health and Cognitive Decline”

🗓️ September 9, 2025 | 🕐 1PM (EST) / 10AM (PST)
Tinnitus is more than “ringing in the ears.” It has important connections to cognitive function and emotional well-being. In this free 60-minute webinar, leading experts will share practical insights on how providers can better support patients living with tinnitus.

🎙️ Expert Panel:
• Ruth Morin, Ph.D., Hoag Memorial Hospital Presbyterian
• Patrick A. Lynch, Esq., MBA, CEO of the American Tinnitus Association
• Dr. Keith Darrow, PhD, CCC-A, AuDExperts
• Joy Siegel, EdD, MBA (Moderator), Nova Southeastern University

🔗 Register here:
https://bit.ly/4fPHmpW

08/22/2025

🧠 Webinar #2 of 5 | September 18
Join us for the second session in our exclusive 5-part webinar series with James E. Galvin, MD, MPH, Chief Scientific Officer at Cognivue.

📘 Topic: From Screening to Stratification: CARM's Role in Advancing Alzheimer’s Risk Identification

In this session, Dr. Galvin will introduce the Cognivue Amyloid Risk Measure (CARM*)—a newly added, optional feature on the Cognivue Clarity® device. CARM enhances the existing cognitive assessment by providing stratification-level insights that detect the likelihood of amyloid pathology—without requiring invasive or costly testing upfront.

🎯 What You’ll Gain:
• Clinical foundation of CARM based on recently published, peer-reviewed research
• See how CARM enhances traditional cognitive screening with amyloid-related risk insights
• Learn how CARM fits seamlessly into the Cognivue Clarity workflow
• Development, validation, and clinical application of CARM’s predictive model

🎥 Join live or watch on demand: https://bit.ly/4fM4uWn


*patent pending

08/13/2025

🧠 Webinar #1 of 5 | Premieres August 21
Be part of the first in our exclusive 5-part webinar series featuring James E. Galvin, MD, MPH, Chief Scientific Officer at Cognivue.

📘 Topic: Redefining Cognitive Care: Breakthrough Evidence and Clinical Pathways with Cognivue Clarity®

In this opening session, Dr. Galvin will provide a high-level overview of four peer-reviewed publications that highlight the growing clinical utility of Cognivue Clarity—a validated, reliable, and efficient tool for cognitive screening and early detection strategies.

🎯 Whether you’re a clinician, researcher, or healthcare leader, this is your chance to explore the latest evidence and how it’s shaping real-world cognitive care.

🎥 Join live or watch on demand: https://bit.ly/456hQJC

08/07/2025

📢 New Poster Presented at AAIC 2025
We’re excited to share a practical application of recent research from the Alzheimer’s Association International Conference (AAIC):
🧠 Two-Stage Screening for Alzheimer’s Disease Clinical Trial Recruitment Enrichment: Cognivue Clarity® and Plasma pTau217

🔍 Key Insight:
A two-stage screening strategy—using Cognivue Clarity® to assess cognitive function and predict the likelihood of amyloid presence (via the CARM), followed by plasma pTau217 testing—may increase the likelihood of identifying individuals with early Alzheimer’s disease for clinical trial enrollment.

This approach offers a brief, validated, and cost-effective alternative to PET imaging—streamlining recruitment and enabling earlier intervention.

📄 View the poster here: https://bit.ly/3H2kOWl

08/04/2025

🔊 WEBINAR ALERT 🔊
“Decoding Tinnitus: The Unseen Connection to Brain Health and Cognitive Decline”
🗓️ September 9, 2025 | 🕐 1PM (EST) / 10AM (PST)

Tinnitus isn’t just a ringing in the ears—it may be a vital clue to broader brain health. Join us for a compelling 60-minute webinar where leading experts explore connections between tinnitus, cognitive function, and emotional well-being.

🗣️ Meet Our Experts:
- Ruth Morin, PhD, Hoag Memorial Hospital Presbyterian
- Patrick A. Lynch, Esq., MBA, CEO of the American Tinnitus Association
- Keith Darrow, PhD, CCC-A, AuDExperts
- Joy Siegel, EdD, MBA (Moderator), Nova Southeastern University

🧠 It’s time to rethink how we support patients with tinnitus.

🔗 Register: https://bit.ly/46EA5ag

07/30/2025

📢 Happening today! Stop by our poster presentation at !
📌 Poster #259 | Wednesday, July 30 | 🕢 7:30 AM – 4:15 PM
🧪 “Two Stage Screening for Alzheimer’s Disease Clinical Trial Recruitment Enrichment: Cognivue Clarity® and Plasma pTau217”

07/24/2025

🧠 Cognivue is heading to Toronto for the 2025 Alzheimer’s Association International Conference (AAIC) – happening July 27–31!

📅 Don’t miss the chance to connect with Paul W. Estes, President & CEO, and Dr. James E. Galvin, Chief Scientific Officer. Email events@cognivue.com to schedule a meeting.

📍 Catch our poster presentation!
📌 Poster #259 | Wednesday, July 30 | 7:30 AM – 4:15 PM
🧪 “Two Stage Screening for Alzheimer’s Disease Clinical Trial Recruitment Enrichment: Cognivue Clarity® and Plasma pTau217”

We’re excited to share our research and contribute to the future of Alzheimer’s care. See you there!

07/22/2025

Join us for a 5-Part Webinar Series featuring James E. Galvin, MD, MPH, Chief Scientific Officer at Cognivue. The first webinar airs on August 21 and is titled “Redefining Cognitive Care: Breakthrough Evidence and Clinical Pathways with Cognivue Clarity.” In this webinar, Dr. Galvin will review and discuss four peer-reviewed publications that represent the continued evolution of Cognivue Clarity as a critical tool in cognitive assessment and early detection strategies.

Register Now: https://bit.ly/3GToRUL

07/21/2025

New short video on NeurologyLive of Dr. James E. Galvin, MD, MPH, Chief Scientific Officer at Cognivue. In the video, he discusses the clinical use of Cognivue Clarity and its new Cognivue Amyloid Risk Measure (CARM)*, and how it can inform clinical decisions and help determine the appropriate next staging sequence for patients.

WATCH IT: https://bit.ly/4o0ncNP

Cognivue Clarity, a 10-minute digital cognitive assessment tool, is intended to aid licensed clinicians in the assessment of cognitive function.

CARM data was derived from the Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation.


*patent pending
Reference: Galvin JE, Kleiman MJ, Harris HM, Estes PW. The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue Clarity. Neurology & Therapy. 2025;14:865-880. doi:10.1007/s40120-025-00741-x

The professor of neurology at the University of Miami Miller School of Medicine provided context on the clinical use of the Cognivue Amyloid Risk Measure in the context of Alzheimer disease care. [WATCH TIME: 3 minutes]